TVTX insider transaction filings
Travere Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-19. Screen TVTX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-19 | 4 | LYONS GARY A — Director | Option exercise (M): 5,000 @ $17.44 · Sale (S): 1,900 @ $62.53 · Sale (S): 2,600 @ $63.50 · Sale (S): 500 @ $64.16 · Option exercise (M): 5,000 @ $17.44 · Sale (S): 4,100 @ $63.27 · +3 more | EDGAR |
| 2026-06-22 | 4 | Inrig Jula — CHIEF MEDICAL OFFICER | Gift (G): 468 @ $0 | EDGAR |
| 2026-06-16 | 4 | Baynes Roy D. — Director | Option exercise (M): 4,500 @ $21.38 · Sale (S): 4,500 @ $50 · Option exercise (M): 4,500 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Coughlin Timothy — Director | Option exercise (M): 10,000 @ $26.52 · Sale (S): 10,000 @ $50.07 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Baynes Roy D. — Director | Grant/award (A): 4,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Poole Sandra — Director | Grant/award (A): 4,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Bruhn Suzanne Louise — Director | Grant/award (A): 4,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Meckler Jeffrey A — Director | Grant/award (A): 4,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Orwin John A — Director | Grant/award (A): 4,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Squarer Ron — Director | Grant/award (A): 4,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Coughlin Timothy — Director | Grant/award (A): 4,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Williams Brinkley Ruth — Director | Grant/award (A): 4,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | LYONS GARY A — Director | Grant/award (A): 4,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2026-05-19 | 4 | Coughlin Timothy — Director | Sale (S): 3,250 @ $43.49 | EDGAR |
| 2026-05-06 | 4 | Cline Christopher R. — CHIEF FINANCIAL OFFICER | Option exercise (M): 4,250 @ $0 · Sale (S): 2,181 @ $46.65 · Sale (S): 310 @ $43.95 · Grant/award (A): 8,500 (derivative) @ $0 · Option exercise (M): 4,250 (derivative) @ $0 | EDGAR |
| 2026-05-06 | 4 | Inrig Jula — CHIEF MEDICAL OFFICER | Option exercise (M): 20,000 @ $22.40 · Sale (S): 20,000 @ $45 · Option exercise (M): 4,250 @ $0 · Sale (S): 2,174 @ $46.65 · Sale (S): 311 @ $43.95 · Option exercise (M): 20,000 (derivative) @ $0 · +2 more | EDGAR |
| 2026-05-06 | 4 | Heerma Peter — CHIEF COMMERCIAL OFFICER | Option exercise (M): 4,250 @ $0 · Sale (S): 2,174 @ $46.65 · Grant/award (A): 8,500 (derivative) @ $0 · Option exercise (M): 4,250 (derivative) @ $0 | EDGAR |
| 2026-05-06 | 4 | Dube Eric M — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 22,500 @ $0 · Sale (S): 22,500 @ $43.95 · Grant/award (A): 45,000 (derivative) @ $0 · Option exercise (M): 22,500 (derivative) @ $0 | EDGAR |
| 2026-05-06 | 4 | ROTE WILLIAM E. — Chief Research Officer | Option exercise (M): 4,250 @ $0 · Sale (S): 2,763 @ $43.95 · Grant/award (A): 8,500 (derivative) @ $0 · Option exercise (M): 4,250 (derivative) @ $0 | EDGAR |
| 2026-05-06 | 4 | Baynes Roy D. — Director | Option exercise (M): 4,500 @ $18.27 · Sale (S): 4,500 @ $46.65 · Option exercise (M): 4,500 (derivative) @ $0 | EDGAR |
| 2026-05-06 | 4 | Meckler Jeffrey A — Director | Option exercise (M): 8,000 @ $16.33 · Sale (S): 8,000 @ $45 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2026-05-06 | 4 | REED ELIZABETH E — Chief Legal Officer and GC | Option exercise (M): 20,000 @ $17.96 · Sale (S): 20,000 @ $45 · Option exercise (M): 4,250 @ $0 · Sale (S): 2,174 @ $46.65 · Sale (S): 2,076 @ $43.95 · Option exercise (M): 20,000 (derivative) @ $0 · +2 more | EDGAR |
| 2026-05-04 | 4 | Baynes Roy D. — Director | Option exercise (M): 9,750 @ $6.82 · Sale (S): 9,750 @ $44.22 · Option exercise (M): 9,750 (derivative) @ $0 | EDGAR |
| 2026-04-23 | 4 | ROTE WILLIAM E. — Chief Research Officer | Sale (S): 9,100 @ $39.09 | EDGAR |
| 2026-04-16 | 4 | Calvin Sandra — SVP, CHIEF ACCOUNTING OFFICER | Option exercise (M): 2,500 @ $22.40 · Option exercise (M): 6,250 @ $8.93 · Option exercise (M): 6,500 @ $20.46 · Sale (S): 21,977 @ $41.07 · Option exercise (M): 2,500 (derivative) @ $0 · Option exercise (M): 6,250 (derivative) @ $0 · +1 more | EDGAR |
| 2026-04-16 | 4 | Baynes Roy D. — Director | Option exercise (M): 8,000 @ $17.94 · Option exercise (M): 9,000 @ $15.43 · Option exercise (M): 4,500 @ $18.27 · Option exercise (M): 4,500 @ $21.38 · Option exercise (M): 6,750 @ $17.11 · Sale (S): 26,000 @ $41.07 · +6 more | EDGAR |
| 2026-04-16 | 4 | LYONS GARY A — Director | Option exercise (M): 8,000 @ $16.33 · Sale (S): 8,000 @ $41.07 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2026-04-15 | 4 | Cline Christopher R. — CHIEF FINANCIAL OFFICER | Grant/award (A): 14,000 @ $0 · Sale (S): 65 @ $28.85 · Sale (S): 9 @ $41.07 · Sale (S): 7,239 @ $41.93 · Sale (S): 1,014 @ $42.61 | EDGAR |
| 2026-04-15 | 4 | Inrig Jula — CHIEF MEDICAL OFFICER | Grant/award (A): 14,000 @ $0 · Sale (S): 7,215 @ $41.93 · Sale (S): 1,018 @ $42.61 | EDGAR |
| 2026-04-15 | 4 | Heerma Peter — CHIEF COMMERCIAL OFFICER | Grant/award (A): 14,000 @ $0 · Sale (S): 7,215 @ $41.93 | EDGAR |
| 2026-04-15 | 4 | Dube Eric M — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 64,000 @ $0 · Sale (S): 56,815 @ $41.01 · Sale (S): 7,165 @ $41.75 · Sale (S): 20 @ $42.66 | EDGAR |
| 2026-04-15 | 4 | ROTE WILLIAM E. — Chief Research Officer | Grant/award (A): 14,000 @ $0 | EDGAR |
| 2026-04-15 | 4 | REED ELIZABETH E — Chief Legal Officer and GC | Grant/award (A): 14,000 @ $0 · Option exercise (M): 10,000 @ $19.08 · Option exercise (M): 20,000 @ $17.96 · Option exercise (M): 7,500 @ $15.46 · Sale (S): 37,500 @ $41.07 · Sale (S): 7,215 @ $41.93 · +5 more | EDGAR |
| 2026-04-07 | 4 | Baynes Roy D. — Director | Option exercise (M): 10,000 @ $26.52 · Sale (S): 10,000 @ $33 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Dube Eric M — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 60,000 @ $15.46 · Sale (S): 34,902 @ $30.55 · Sale (S): 25,098 @ $31.46 · Option exercise (M): 60,000 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | REED ELIZABETH E — Chief Legal Officer and GC | Option exercise (M): 10,000 @ $15.46 · Sale (S): 10,000 @ $30 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-03-18 | 4 | REED ELIZABETH E — Chief Legal Officer and GC | Option exercise (M): 10,000 @ $19.08 · Sale (S): 10,000 @ $28.09 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | Dube Eric M — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 60,000 @ $15.46 · Sale (S): 60,000 @ $30.10 · Option exercise (M): 60,000 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | REED ELIZABETH E — Chief Legal Officer and GC | Option exercise (M): 10,000 @ $19.08 · Sale (S): 5,679 @ $27.50 · Sale (S): 4,321 @ $28.26 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4 | Cline Christopher R. — CHIEF FINANCIAL OFFICER | Sale (S): 1,635 @ $32.14 · Sale (S): 110 @ $32.90 | EDGAR |
| 2026-02-05 | 4 | Inrig Jula — CHIEF MEDICAL OFFICER | Sale (S): 1,547 @ $32.11 · Sale (S): 232 @ $32.85 | EDGAR |
| 2026-02-05 | 4 | REED ELIZABETH E — Chief Legal Officer and GC | Sale (S): 2,485 @ $32.07 · Sale (S): 509 @ $32.74 | EDGAR |
| 2026-02-03 | 4 | Cline Christopher R. — CHIEF FINANCIAL OFFICER | Grant/award (A): 28,130 @ $0 · Sale (S): 7,242 @ $32.12 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Inrig Jula — CHIEF MEDICAL OFFICER | Grant/award (A): 28,130 @ $0 · Sale (S): 6,956 @ $32.12 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Calvin Sandra — SVP, CHIEF ACCOUNTING OFFICER | Grant/award (A): 15,180 @ $0 · Sale (S): 4,333 @ $32.12 · Grant/award (A): 20,160 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Heerma Peter — CHIEF COMMERCIAL OFFICER | Grant/award (A): 26,120 @ $0 · Sale (S): 7,310 @ $32.12 · Grant/award (A): 69,640 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Dube Eric M — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 113,800 @ $0 · Sale (S): 66,452 @ $32.06 · Sale (S): 33,635 @ $32.70 · Grant/award (A): 303,600 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | ROTE WILLIAM E. — Chief Research Officer | Grant/award (A): 20,090 @ $0 · Sale (S): 12,446 @ $32.87 · Grant/award (A): 53,570 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | REED ELIZABETH E — Chief Legal Officer and GC | Grant/award (A): 25,110 @ $0 · Sale (S): 7,175 @ $32.12 · Grant/award (A): 66,960 (derivative) @ $0 | EDGAR |
| 2026-01-27 | 4 | Dube Eric M — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 8,135 @ $15.46 · Sale (S): 8,135 @ $30.01 · Option exercise (M): 51,865 @ $15.46 · Sale (S): 51,865 @ $30.10 · Option exercise (M): 8,135 (derivative) @ $0 · Option exercise (M): 51,865 (derivative) @ $0 | EDGAR |
Recent 8-K events — Travere Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-21 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-14 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-02-19 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-13 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TVTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →